Want to join the conversation?
$CELG 2Q15 PR: "The Celgene team delivered exceptional results across the portfolio in the second quarter. Continue to invest strategically in the long-term future of Celgene & expect our recently announced transactions with AstraZeneca, Juno and Receptos to accelerate our earnings growth beginning in 2019,” said Bob, CEO.
$NFLX a monster move, going up. Expect making some money on Monday.
$AMD down more than 6% even after posting above consensus third quarter results.
$MCD stock rose more than 2% after it posted better than expected 3Q16 results, driven by global same-store sales growth. Meanwhile, earnings and revenue were lower than last year, hurt by refranchising efforts.